Are Dividend Giants BHP Billiton plc, GlaxoSmithKline plc And HSBC Holdings plc Worth A Buy?

Are Dividend Giants BHP Billiton plc (LON:BLT), GlaxoSmithKline plc (LON:GSK) And HSBC Holdings plc (LON:HSBA) Worth A Buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

These dividend giants all pay out huge yields that are great for any portfolio. As you can see in the table below all three companies pay more than 6% dividend yield against a FTSE 100 average yield of 4%. Income stocks are becoming a popular addition to many portfolios and should be part of every investor’s research. The three companies listed below are some of the UK’s most popular stocks. 

  Dividend
Yield
Dividend
Cover
BHP 11.7% 0.4
GlaxoSmithKline 6.17% 0.83
HSBC 6.3% 1.58

BHP Billiton

BHP Billiton (LSE: BLT), like many other commodity-based companies, has had a year to forget. Commodity prices are falling ever lower and the company has recently had an environmental disaster in Brazil where 13 people died in a dam burst. The company pays a huge dividend that is coming under threat due to declining revenues and a possible $3.5bn fine for the dam burst in Brazil. 

The dividend cover of 0.4 is less than reassuring, too, and commodity prices don’t look like shooting higher any time soon. Investors that buy the shares now and hold for the long term may well be rewarded well, but should expect short term pain first. 

GlaxoSmithKline

GlaxoSmithKline’s (LSE: GSK) share price has also been under increased pressure, due to blockbuster drugs coming off patent. This has come as a slight surprise to many, as Glaxo has an exiting pipeline of new drugs that should boost company earnings and fill the earnings gap. City analysts forecast strong earnings growth in 2016 and 2017, which should also give strength to its dividend.

At a current yield of 6.1% it looks a solid bet for the next few years, with big growth prospects for such a large company. 

HSBC

HSBC (LSE: HSBA) currently has a P/E ratio of just over 9.5, which implies the company is undervalued and has scope for growth. This growth should be provided by HSBC’s emerging market business and 2016 looks like it may be a good year in these emerging countries. China and India have both had good growth numbers come out in the last few weeks which is encouraging. The company has also identified billions worth of savings that should do wonders for the bank going forward. 

The three companies listed here all offer various risk profiles that should always be taken into account before investing. BHP is the ‘higher risk’ company, due to the declining commodities environment, and its dividend may well have to be cut to conserve cash. It does however offer the highest yield in the FSTE 100,  so for brave investors that believe in the company this could well be the buying opportunity of the decade. GlaxoSmithKline and HSBC are ‘lower risk’ plays, offering solid income with growth prospects too. 

Jack Dingwall has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and HSBC Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

British pound data
Investing Articles

Starting with nothing? Here’s why now is the perfect time to start building a passive income

Many are worried that 2026 might be a bad time to start investing in stocks and shares. Our Foolish author…

Read more »

ISA coins
Investing Articles

Decided not to bother with a Stocks and Shares ISA? You might be missing these 3 things!

With a fresh annual allowance for contributing to a Stocks and Shares ISA upon us, what might people who don't…

Read more »

GSK scientist holding lab syringe
Investing Articles

Why is everyone buying GSK shares?

GSK shares have been outperforming the FTSE 100 in 2026. Paul Summers takes a closer look and asks whether this…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

£10,000 invested in easyJet shares at the start of 2026 is now worth…

Anyone buying easyJet shares will have endured a rough ride since January. Paul Summers wonders whether things could get even…

Read more »

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Investing Articles

5 years ago, £5,000 bought 2,645 Barclays shares. But how many would it buy now?

Despite delivering an impressive return since April 2021, Barclays' shares have lagged the FTSE 100's other banks. James Beard considers…

Read more »

Side of boat fuelled by gas to liquids, advertising Shell GTL Fuel
Investing Articles

5 years ago, £5,000 bought 354 Shell shares. But how many would it buy now?

When it comes to Shell’s numbers, most of them are impressive. And it’s no different when looking at the recent…

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

I asked ChatGPT if I should buy Aviva, Diageo or BAE Systems stock and it said…

Aviva, Diageo and BAE Systems shares are popular FTSE 100 picks. But which of the three does ChatGPT like the…

Read more »

Tesla car at super charger station
Investing Articles

SpaceX’s IPO threatens to leave the Tesla share price on the forecourt

As Elon Musk starts fuelling the engines for a SpaceX IPO, could the Tesla share price get left in the…

Read more »